Ichiro Tsunematsu, Yasuhiro Ogura, Kayoko Inoue, Akio Koizumi, Nobuhiko Tanigawa, Koichi Tanaka – 18 May 2006 – Adult‐to‐adult living donor liver transplantation (ALDLT) has been accepted as an important option for end‐stage liver disease, but information regarding the risk factors remains fragmentary. We aimed to establish a predictive model for 90‐day survival. In the first step, a total of 286 cases who had received primary ALDLT using a right lobe graft between 1998 and 2004 were randomly divided into 2 cohorts at a ratio of 2:1 (191 vs. 95 recipients).

Luca Aldrighetti, Carlo Pulitanò, Marcella Arru, Renato Finazzi, Marco Catena, Laura Soldini, Laura Comotti, Gianfranco Ferla – 18 May 2006 – Hepatic injury secondary to warm ischemia‐reperfusion (I/R) injury and alterations in haemostatic parameters are often unavoidable events after major hepatic resection. The release of inflammatory mediator is believed to play a significant role in the genesis of these events. It has been suggested that preoperative steroid administration may reduce I/R injury and improve several aspects of the surgical stress response.

Thierry Gustot, Arnaud Lemmers, Christophe Moreno, Nathalie Nagy, Eric Quertinmont, Charles Nicaise, Denis Franchimont, Hubert Louis, Jacques Devière, Olivier Le Moine – 20 April 2006 – Gut‐derived, endotoxin‐mediated hepatocellular damage has been postulated to play a crucial role in the pathogenesis of alcohol‐induced liver injury in rodents. Endotoxins induce production of tumor necrosis factor α (TNF‐α) by Kupffer cells via Toll‐like receptor (TLR) 4 and contribute to liver injury. This study addressed the contribution of other TLRs and ligands to alcoholic fatty liver.

Albert Mennone, Carol J. Soroka, Shi‐Ying Cai, Kathy Harry, Masashi Adachi, Lee Hagey, John D. Schuetz, James L. Boyer – 20 April 2006 – Mrp4 is a member of the multidrug resistance–associated gene family that is expressed on the basolateral membrane of hepatocytes and undergoes adaptive upregulation in response to cholestatic injury or bile acid feeding. However, the relative importance of Mrp4 in a protective adaptive response to cholestatic injury is not known.

George N. Ioannou, Noel S. Weiss, Edward J. Boyko, Dariush Mozaffarian, Sum P. Lee – 20 April 2006 – In the United States, elevated serum alanine aminotransferase (ALT) activity in the absence of viral hepatitis or excessive alcohol consumption is most commonly attributed to nonalcoholic fatty liver disease (NAFLD). NAFLD is related to predictors of coronary heart disease (CHD) such as insulin resistance and central obesity. We examined the association between elevated serum ALT activity and the 10‐year risk of CHD as estimated using the Framingham risk score (FRS).

Kevin D. Mullen, Ravi K. Ghanta, Brian S. Putka – 20 April 2006

20 April 2006

Mario Cruciani, Carlo Mengoli, Marina Malena, Oliviero Bosco, Giovanni Serpelloni, Paolo Grossi – 20 April 2006 – We performed a meta‐analysis to determine whether antifungal prophylaxis decreases infectious morbidity and mortality in liver transplant patients. We searched for randomized trials dealing with prophylaxis with systemic antifungal agents. We used a fixed effect model, with risk ratio (RR) and 95% confidence interval (CI); we assessed study quality for heterogeneity and publication bias.

Carla Kuiken, Masashi Mizokami, Gilbert Deleage, Karina Yusim, Francois Penin, Tadasu Shin‐I, Céline Charavay, Ning Tao, Daniel Crisan, Delphine Grando, Anita Dalwani, Christophe Geourjon, Ashish Agrawal, Christophe Combet – 20 April 2006 – Part of the effort to develop hepatitis C–specific drugs and vaccines is the study of genetic variability of all publicly available HCV sequences. Three HCV databases are currently available to aid this effort and to provide additional insight into the basic biology, immunology, and evolution of the virus.

Takuma Teratani, Haruhiko Yoshida, Shuichiro Shiina, Shuntaro Obi, Shinpei Sato, Ryosuke Tateishi, Norio Mine, Yuji Kondo, Takao Kawabe, Masao Omata – 20 April 2006 – We evaluated the efficacy and safety of radiofrequency (RF) ablation for hepatocellular carcinoma (HCC) in presumably high‐risk locations. Between February 1999 and December 2001, we performed RF ablation on 1,419 nodules in 636 consecutive HCC patients, of which 231 nodules in 207 patients were in high‐risk locations, defined as less than 5 mm from a large vessel or an extrahepatic organ.